The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00148720
Recruitment Status :
First Posted : September 8, 2005
Last Update Posted : November 11, 2015
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Information provided by (Responsible Party):
Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute
The purpose of this study is to find out what effects (good and bad) taking capecitabine for 12 weeks before surgery will have on women with breast cancer.
Condition or disease
Invasive Breast CarcinomaPrimary Invasive Breast CancerStage I Breast CancerStage II Breast CancerStage III Breast Cancer
Prior to the start of treatment, patients will have a small metal clip inserted into the tumor bed to identify the tumor site to the surgeon. At that time, a needle biopsy of the breast tumor or a sentinel (underarm) lymph node biopsy will also be performed.
Patients will take capecitabine orally twice daily for 14 days. This treatment will repeat every 21 days (1 cycle). Patients will receive 4 cycles of this treatment.
A physical exam and blood work will be done every three weeks after starting therapy to monitor side effects.
After two weeks of capecitabine a biopsy from the tumor will be done to generate information about the characteristics of the tumor that may respond to capecitabine.
After completing 4 cycles (12 weeks) of capecitabine, patients will then undergo surgery to remove any remaining breast cancer (lumpectomy or mastectomy). Post-surgical treatment (radiation, chemotherapy, and hormonal therapy) is at the discretion of the patients physician.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histological confirmation of primary invasive breast cancer
Stage I-III operable breast cancer.
Primary tumor must be greater than or equal to 2cm by radiographic imaging or palpitation
Women greater than 18 years of age
ECOG performance status 0-1
WBC > 4000/mm3
Platelet count > 100,000/mm3
SGOT < 2x ULN
Calculated creatinine clearance > 50ml/min
Evidence of metastatic (stage IV) cancer on physical exam or any diagnostic study.
Pregnant or breast-feeding women
Inflammatory breast cancer
HER2 positive disease
History of hypersensitivity to a 5-FU or known dihydropyrimidine dehydrogenase (DPD) deficiency
Uncontrolled intercurrent illness
Prior history of breast cancer are ineligible except: diagnosed at least 2 years ago; present cancer is not in previously irradiated breast; no prior chemotherapy in the past 5 years; no prior high-dose chemotherapy with stem cell or bone marrow transplant.
Excisional biopsy performed prior to enrollment
Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.